| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks | Chief Legal Officer and EVP
1 company
Thomas DesRosier is See Remarks at MCRB. Thomas DesRosier's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $16K at current prices.
Historically, Thomas DesRosier's trades have earned a middling insider score of 69/100 across 12 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +14.9%.
The MCRB filings lean toward selling, a net 28,664 shares.
Thomas DesRosier has 26 Form 4 filings on record from June 2016 to August 2026, all as Seres Therapeutics (MCRB), 2016–2026.
The 54 reported transactions were 20 option exercises, 18 option or other derivative awards, 15 open-market sales and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 15 sales worth about $93K.
The largest open-market sale was 3,475 shares of MCRB at an average $11.02 on January 26, 2018, about $38K.
All 13 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 82 | $4.55 | $373.10 | -1.0% | - | - | |
| May 18, 2026 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 79 | $7.53 | $594.87 | -1.0% | -40.6% | - | |
| Feb 15, 2026 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 78 | $8.47 | $660.66 | -1.0% | -7.7% | - | |
| Nov 15, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 76 | $17.30 | $1,314.80 | -1.0% | -49.2% | - | |
| Aug 18, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 76 | $16.65 | $1,265.40 | -1.0% | +22.3% | -75.5% | |
| May 15, 2025 | MCRB Seres Therapeutics, Inc. | Chief Legal Officer and EVP | Sale+OE10b5-1 | 79 | $7.28 | $575.12 | -1.1% | +115.5% | +3.1% | |
| Feb 18, 2025 | MCRB Seres Therapeutics, Inc. | Chief Legal Officer and EVP | Sale+OE10b5-1 | 4,300 | $0.81 | $3,485.15 | -2.9% | -52.0% | -50.5% | |
| Nov 18, 2024 | MCRB Seres Therapeutics, Inc. | Chief Legal Officer and EVP | Sale+OE10b5-1 | 878 | $0.54 | $474.73 | -0.6% | +43.6% | +113.4% | |
| Oct 28, 2024 | MCRB Seres Therapeutics, Inc. | Chief Legal Officer and EVP | Sale+OE10b5-1 | 4,259 | $0.69 | $2,939.14 | -3.1% | +20.2% | +22.6% | |
| Aug 16, 2024 | MCRB Seres Therapeutics, Inc. | Chief Legal Officer and EVP | Sale+OE10b5-1 | 873 | $0.84 | $733.32 | -0.7% | -32.7% | -5.1% |